Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266

1.

Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.

Strand V, Schett G, Hu C, Stevens RM.

J Rheumatol. 2013 Jul;40(7):1158-65. doi: 10.3899/jrheum.121200. Epub 2013 Apr 15.

PMID:
23588944
2.
3.
4.

Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.

Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.

J Rheumatol. 2010 Jun;37(6):1221-7. doi: 10.3899/jrheum.091093. Epub 2010 Apr 15.

5.

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.

Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL.

J Rheumatol. 2012 Jul;39(7):1450-7. doi: 10.3899/jrheum.111375. Epub 2012 Jun 1.

6.
7.

Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.

J Rheumatol. 2015 Mar;42(3):479-88. doi: 10.3899/jrheum.140647. Epub 2015 Jan 15.

8.

Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.

Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1666-73. doi: 10.1002/acr.22044.

9.

Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.

J Rheumatol. 2008 Jan;35(1):20-30. Epub 2007 Nov 15.

PMID:
18050385
10.

Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.

Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.

J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1.

11.

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.

Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB.

Curr Med Res Opin. 2010 Oct;26(10):2385-92. doi: 10.1185/03007995.2010.515804.

PMID:
20831455
12.

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL.

Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627.

14.

The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.

Bingham CO 3rd, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R.

J Rheumatol. 2014 Jun;41(6):1067-76. doi: 10.3899/jrheum.130864. Epub 2014 May 1.

PMID:
24786931
15.

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.

Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.

16.

Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools.

Strickland G, Pauling J, Cavill C, McHugh N.

Clin Rheumatol. 2012 Aug;31(8):1215-22. doi: 10.1007/s10067-012-1997-1. Epub 2012 May 16.

PMID:
22588647
17.

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.

Strand V, Kremer J, Wallenstein G, Kanik KS, Connell C, Gruben D, Zwillich SH, Fleischmann R.

Arthritis Res Ther. 2015 Nov 4;17:307. doi: 10.1186/s13075-015-0825-9.

18.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.

Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.

19.

Evaluating the correlation and responsiveness of patient-reported pain with function and quality-of-life outcomes after spine surgery.

DeVine J, Norvell DC, Ecker E, Fourney DR, Vaccaro A, Wang J, Andersson G.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S69-74. doi: 10.1097/BRS.0b013e31822ef6de. Review.

PMID:
21897347

Supplemental Content

Support Center